Author initiates a Pfizer position citing non-COVID growth, cost savings, debt reduction, a GLP-1 Phase 3 catalyst, and a cheap valuation with a 6%+ dividend yield.
PFE — LONG The author is initiating and building a Pfizer position, arguing the non-COVID portfolio grew 6% operationally and management is on track for $7.2 billion in net savings by end of 2026, a year early. He views the paused buyback as prudent given high debt, and cites a catalyst of 20 pivotal Phase 3 trials including GLP-1 from the Metsera acquisition this year. Valuation is cheap at 9.34x forward PE and under 10x EV/EBIT with a 6%+ dividend yield. Stated risks are the COVID cliff, future patent cliff, and high debt burden.
I am initiating a position and will continue to build over pullbacks.
This Reddit post, published February 12, 2026, features u/Key_Variety_6287 discussing PFE. 1 trade idea extracted by AI with direction and confidence scoring.
Speakers: u/Key_Variety_6287 · Tickers: PFE